How much revenue does Jiangsu Lianhuan Pharmaceutical make?

Jiangsu Lianhuan Pharmaceutical reported 2.16 billion CNY in revenue for fiscal year 2024, down 0.6% from 2.17 billion CNY in fiscal year 2023. In Q1 2026 revenue was 810.63 million CNY.

What is Jiangsu Lianhuan Pharmaceutical's largest business segment?

Medicine Circulation, with 1.60 billion CNY or 59% of segment revenue in fiscal year 2025. Next: Pharmaceutical Manufacturing (41%).

Where does Jiangsu Lianhuan Pharmaceutical make most of its revenue?

China: 98% of revenue by region in fiscal year 2025, followed by Overseas (2%).

What companies are similar to Jiangsu Lianhuan Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Kexing Biopharm Co., Ltd. (688136.SS), Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ), Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ), Sinotherapeutics Inc. (688247.SS).

Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SS) Stock

About Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, dapoxetine hydrochloride, milrinone injection, aprilite, ebastine tablets, felodipine tablets, ta...

At a glance

Jiangsu Lianhuan Pharmaceutical reported revenue of 2.16 billion CNY for fiscal year 2024, down 0.6% from fiscal year 2023, and net income of 84.16 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 810.63 million CNY, up 29.1% from a year before. Its largest business segment, Medicine Circulation, brought in 59% of segment revenue in fiscal year 2025; China was the largest region with 98%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.